Information Provided By:
Fly News Breaks for August 3, 2015
AGN
Aug 3, 2015 | 07:24 EDT
JPMorgan analyst Chris Schott reinstated shares of Allergan with an Overweight rating following a period of restriction and raised his price target for the stock to $400 from $375. Allergan's generics business sale repositions the company as a pure-play branded pharma name with limited patent risk and significant grow potential, Schott tells investors.
News For AGN From the Last 2 Days
There are no results for your query AGN